Joseph Stringer
Stock Analyst at Needham
(4.58)
# 224
Out of 5,128 analysts
325
Total ratings
49.48%
Success rate
38.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $90 → $110 | $46.06 | +138.82% | 18 | Jan 7, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $120 → $145 | $101.59 | +42.73% | 28 | Dec 11, 2025 | |
| CDTX Cidara Therapeutics | Downgrades: Hold | n/a | $221.38 | - | 17 | Nov 14, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $133 → $140 | $124.35 | +12.59% | 9 | Nov 13, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $78 → $90 | $83.17 | +8.21% | 25 | Oct 30, 2025 | |
| RNA Avidity Biosciences | Downgrades: Hold | $65 | $72.37 | -10.18% | 19 | Oct 27, 2025 | |
| MRNA Moderna | Reiterates: Hold | n/a | $35.89 | - | 9 | Oct 20, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $22 → $35 | $35.17 | -0.48% | 24 | Oct 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $377 → $478 | $422.50 | +13.14% | 23 | Jul 31, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $18.08 | +54.87% | 52 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $6.16 | +127.27% | 18 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $11 | $5.53 | +98.92% | 19 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $29 | $26.49 | +9.48% | 20 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $484.15 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.17 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.35 | +640.74% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $27.42 | +34.94% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $18.88 | -4.66% | 2 | Aug 24, 2021 |
Vaxcyte
Jan 7, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $46.06
Upside: +138.82%
Rhythm Pharmaceuticals
Dec 11, 2025
Maintains: Buy
Price Target: $120 → $145
Current: $101.59
Upside: +42.73%
Cidara Therapeutics
Nov 14, 2025
Downgrades: Hold
Price Target: n/a
Current: $221.38
Upside: -
Gilead Sciences
Nov 13, 2025
Maintains: Buy
Price Target: $133 → $140
Current: $124.35
Upside: +12.59%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $78 → $90
Current: $83.17
Upside: +8.21%
Avidity Biosciences
Oct 27, 2025
Downgrades: Hold
Price Target: $65
Current: $72.37
Upside: -10.18%
Moderna
Oct 20, 2025
Reiterates: Hold
Price Target: n/a
Current: $35.89
Upside: -
Stoke Therapeutics
Oct 10, 2025
Maintains: Buy
Price Target: $22 → $35
Current: $35.17
Upside: -0.48%
Alnylam Pharmaceuticals
Jul 31, 2025
Maintains: Buy
Price Target: $377 → $478
Current: $422.50
Upside: +13.14%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $18.08
Upside: +54.87%
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $6.16
Upside: +127.27%
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $5.53
Upside: +98.92%
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $26.49
Upside: +9.48%
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $484.15
Upside: -
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.17
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.35
Upside: +640.74%
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $27.42
Upside: +34.94%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $18.88
Upside: -4.66%